Table 2 Properties of post-approval trajectories.
| Â | Â | Number of trajectories |
|---|---|---|
Trajectory property | Industry initiated | 66 (18%)a |
Biomarker enriched | 107 (24%) | |
Trajectory outcomes | Secondary FDA approval | 14 (3%) |
NCCN off-label recommendation | 14 (3%) | |
Secondary FDA approval presenting substantial clinical benefit (ESMO-MCBS) | 4 (1%) | |
Trajectory drug type | Immunotherapy | 97 (22%) |
Cytotoxic therapy | 15 (3%) | |
Targeted therapy | 339 (75%) |
